Pharmacogenetics of drug transporters and its impact on the pharmacotherapy

Current Topics in Medicinal Chemistry

Volumn 4, Issue 13, 2004, Pages 1385-1398

  Sakaeda, Toshiyuki ^a   Nakamura, Tsutomu ^a   Okumura, Katsuhiko ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Disease risk; Expression; Function; Haplotype analysis; MDR1; P glycoprotein; Pharmacodynamics; Pharmacokinetics; Single nucleotide polymorphism (SNP)

Indexed keywords

ABC TRANSPORTER; ADEFOVIR; AMANTADINE; ANTINEOPLASTIC AGENT; BETA LACTAM ANTIBIOTIC; CIDOFOVIR; CIMETIDINE; CYCLOSPORIN A; DACTINOMYCIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DRUG METABOLIZING ENZYME; ETOPOSIDE; FEXOFENADINE; GENE PRODUCT; GLYCOPROTEIN P; GLYCOSYLATED PROTEIN; MEMBRANE PROTEIN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PRAVASTATIN; PROSTAGLANDIN E2; QUINIDINE; SULINDAC; TOPOTECAN; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE;

BRAIN LEVEL; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; DRUG TRANSPORT; DUODENUM; ENTERITIS; GENE FUNCTION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HEPATOBILIARY SYSTEM; HUMAN; INTESTINE ABSORPTION; KIDNEY TUBULE EXCRETION; KIDNEY TUMOR; MULTIDRUG RESISTANCE; NONHUMAN; PARKINSON DISEASE; PHARMACODYNAMICS; PHARMACOGENOMICS; PROTEIN FAMILY; REVIEW; RISK FACTOR; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 4544373032     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043387692     Document Type: Review

References (172)

1. Kalow, W. Familial incidence of low pseudocholinesterase level. Lancet 1956, 2, 576.
2. Carson, P.E.; Flanagan, C.L.; Ickes, C.E.; Alving, A.S. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 1956, 124, 484-485.
3. Evans, D.A.P.; Manley, K.A.; McKusick, V.A. Genetic control of isoniazid metabolism in man. Br. Med. J. 1960, 2, 485-491.
4. Evans, W.E.; McLeod, H.L. Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 2003, 348, 538-549.
5. Tribut, O.; Lessard, Y.; Reymann, J.M.; Allain, H.; Bentué-Ferrer, D. Pharmacogenomics. Med. Sci. Monit. 2002, 8, RA152-163.
6. Ambrose, H.J. SNPs and pharmacogenomics. Pharmacogenomics 2002, 3, 583-586.
7. Kalow, W. Pharmacogenetics and personalized medicine. Fundam. Clin. Pharmacol. 2002, 16, 337-342.
8. Kalow, W. Pharmacogenetics in biological perspective. Pharmacol. Rev. 1997, 49, 369-379.
9. Kalow, W.; Tang, B.K.; Endrenyi, L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998, 8, 283-289.
10. Eichelbaum, M.; Burk, O. CYP3A genetics in drug metabolism. Nature Med. 2001, 7, 285-287.
11. Ingelman-Sundberg, M.; Oscarson, M.; McLellan, R.A. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. TiPS 1999, 20, 342-349.
12. Tayeb, M.T.; Clark, C.; Haites, N.E.; Sharp, L.; Murray, G.I.; McLeod, H.L. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br. J. Cancer 2003, 88, 928-932.
13. Nagata, K.; Yamazoe, Y. Genetic polymorphism of human cytochrome P450 involved in drug metabolism. Drug Metabol. Pharmacokin. 2002, 17, 167-189.
14. Lamba, J.K.; Lin, Y.S.; Schuetz, E.G.; Thummel, K.E. Genetic contribution to variable human CYP-3A-mediated metabolism. Adv. Drug Deliv. Rev. 2002, 54, 1271-1294.
15. Sparreboom, A.; Danesi, R.; Ando, Y.; Chan, J.; Figg, W.D. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat. 2003, 6, 71-84.
16. Sakaeda, T.; Nakamura, T.; Okumura, K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol. Pharm. Bull. 2002, 25, 1391-1400.
17. Sakaeda, T.; Nakamura, T.; Okumura, K. Pharmacogenetics of MDR1 and its impact on pharmacokinetics and pharmcodynamics of drugs. Pharmacogenomics 2003, 4, 397-410.
18. Fromm, M.F. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv. Drug Deliv. Rev. 2002, 54, 1295-1310.
19. Tirona, R.G.; Kim, R.B. Pharmacogenomics of drug transporters. In Pharmacogenomics. The Search for Individualized Therapies; Licinio, J.; Wong, M.L.; Eds.; Wiley-VCH Verlag GmbH: Weinheim, Germany, 2002; pp 179-213.
20. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2000, 92, 1295-1302.
21. Russel, F.G.; Masereeuw, R.; van Aubel, R.A. Molecular aspects of renal anionic drug transport. Annu. Rev. Physiol. 2002, 64, 563-594.
22. Sekine, T.; Cha, S.H.; Endou, H. The multispecific organic anion transporter (OAT) family. Pflügers Arch. 2000, 440, 337-350.
23. Inui, K.I.; Masuda, S.; Saito, H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 2000, 58, 944-958.
24. Dresser, M.J.; Leabman, M.K.; Giacomini, K.M. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J. Pharm. Sci. 2001, 90, 397-421.
25. Tamai, I.; Tsuji, A. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 2000, 89, 1371-1388.
26. Mizuno, N.; Sugiyama, Y. Drug transporters: their role and importamnce in the selection and development of new drugs. Drug Metabol. Pharmacokin. 2002, 17, 93-108.
27. Juliano, R.L.; Ling, V. A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976, 455, 152-162.
28. Ueda, K.; Clark, D.P.; Chen, C.; Roninson, I.B.; Gottesman, M.M.; Pastan, I. The human multidrug resistance (mdr1) gene. J. Biol. Chem. 1987, 262, 505-508.
29. Chen, C.J.; Chin, J.E.; Ueda, K.; Clark, D.P.; Pastan, I; Gottesman, M.M.; Roninson, I.B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47, 381-389.
30. Ueda, K.; Cardarelli, C.; Gottesman, M.M.; Pastan, I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicines, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. USA 1987, 84, 3004-3008.
31. Chen, C.; Clark, D.; Ueda, K.; Pastan, I.; Gottesman, M.M.; Roninson, I.B. Gpnomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J. Biol. Chem. 1990, 265, 506-514.
32. Rosenberg, M.F.; Callaghan, R.; Ford, R.C.; Higgins, C.F. Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J. Biol. Chem. 1997, 272, 10685-10694.
33. Ambudkar, S.V.; Dey, S.; Hrycyna, C.A.; Ramachandra, M.; Pastan, I.; Gottesman, M.M. Biochemical, cellular, and pharmacological aspects of the multidrug trasnporter. Annu. Rev. Pharmacol. Toxicol. 1999, 39, 361-398.
34. Higgins, C.F.; Gottesman, M.M. Is the multidrug transporter a flippase? Trends Biochem. Sci. 1992, 17, 18-21.
35. van Helvoort, A.; Smith, A.J.; Sprong, H.; Fritzsche, I.; Schinkel, A.H.; Borst, P.; van Meer, G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996, 87, 507-517.
36. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M.M.; Pastan, I.; Willingham, M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA. 1987, 84, 7735-7738.
37. Kusuhara, H.; Suzuki, H.; Sugiyama, Y. The role of P-glycoprotein andcanalicular miultispecific organic anion transporter in the hepatobiliary excretion of drugs. J. Pharm. Sci. 1998, 97, 1025-1040.
38. Tanigawara, Y. Role of P-glycoprotein in drug disposition. Ther. Drug Monit. 2000, 22, 137-140.
39. Borst, P.; Schinkel, A.H.; Smit, J.J.M.; Wagenaar, E.; van Deemter, L.; Smith, A.J.; Eijdems, E.W.; Baas, F.; Zaman, G.J. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmac. Ther. 1993, 60, 289-299.
40. Watkins, P.B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 1997, 27, 161-170.
41. Hyde, S.C.; Emsley, P.; Hartshorn, M.J.; Mimmack, M.M.; Gileadi, U.; Pearce, S.R.; Gallagher, M.P.; Gill, D.R.; Hubbard, R.E.; Higgins, C.F. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 1990, 346(6282), 362-365.
42. Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily Genome Res. 2001, 11, 1156-1166.
43. Dean, M.; Hamon, Y.; Chimini, G. The human ATP-binding cassette (ABC) transporter superfarmly. J. Lipid Res. 2001, 42, 1007-1017.
44. Matheny, C.J.; Lamb, M.W.; Brouwer, K.L.R.; Pollack, G.M. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001, 21, 778-796.
45. Rodriguez, I.;, Abernethy D.R.; Woosley, R.L. P-glycoprotein in clinical cardiology. Circulation 1999, 99, 472-474.
46. Hunter, J.; Hirst, B.H. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv. Drug Deliv. Rev. 1997, 25, 129-157.
47. Stouch, T.R.; Gudmundsson, O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Deliv. Rev. 2002, 54, 315-328.
48. Fromm, M.F.; Eichelbaum, M. The pharmacogenomics of human P-glycoprotein. In Pharmacogenomics. The Search for Individualized Therapies; Licinio, J.; Wong, M L.; Eds.; Wiley-VCH Verlag GmbH: Weinheim, Germany, 2002; pp 159-178.
49. Wacher, V.J.; Wu, C.Y.; Benet, L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen. 1995, 13, 129-134.
50. Kim, R.B. Drug transporters in HIV therapy. Top. HIV Med. 2003, 11, 136-139.
51. Löcher, W.; Potschka, H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol. Exp. Ther. 2002, 301, 7-14.
52. Wacher, V.J.; Silverman, J.A.; Zhang, Y.; Benet, L.Z. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 1998, 87, 1322-1330.
53. Wandel, C.; Kim, R.B.; Kajiji, S.; Guengerich, F.P.; Wilkinson, G.R.; Wood, A.J.J. P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies. Cancer Res. 1999, 59, 3944-3948.
54. Kim, R.B.; Wandel, C.; Leake, B.; Cvetkovic, M.; Fromm, M.F.; Dempsey, P.J.; Roden, M.M.; Belas, F.; Chaudhary, A.K.; Roden, D.M.; Wood, A.J.; Wilkinson, G.R.. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 1999, 16, 408-414.
55. Tran, C.D.H.; Timmins, P.; Conway, B.R.; Irwin, W.J. Investigation of the coordinated functional activities of cytochrome P450 3A4 and P-glycoprotein in limiting the absorption of xenobiotics in Caco-2 cells. J. Pharm. Sci. 2002, 91, 117-128.
56. de Wildt, S.N.; Kearns, G.L.; Leeder, J.S.; van den Anker, J.N. Cytochrome P4503A. Clin. Pharmacokinet. 1999, 37, 485-505.
57. Bertz, R.J.; Granneman, G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 1997, 32, 210-258.
58. Zhang, Y.; Benet, L.Z. The gut as a barrier to drug absorption. Clin. Pharmacokinet. 2001, 40, 15-168.
59. Sakaeda, T.; Takara, K.; Kakumoto, M.; Ohmoto, N.; Nakamura, T.; Iwaki, K.; Tanigawara, Y.; Okumura, K. Simvastatin and lovastatin, but not pravastatin, interact with MDR1. J. Pharm. Pharmacol. 2002, 54, 419-423.
60. Takara, K.; Kakumoto, M.; Tanigawara, Y.; Funakoshi, J.; Sakaeda, T.; Okumura, K. Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002, 70, 1491-1500.
61. Kakumoto, M.; Takara, K.; Sakaeda, T.; Tanigawara, Y.; Kita, T.; Okumura, K. MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs. Biol. Pharm. Bull. 2002, 25, 1604-1607.
62. Kakumoto, M.; Sakaeda, T.; Takara, K.; Nakamura, T.; Kita, T.; Yagami, T.; Kobayashi, H.; Okamura, N.; Okumura, K. Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil. Cancer Sci. 2003, 94, 81-86.
63. Callen, D.F.; Baker, E.; Simmers, R.N.; Seshadri, R.; Roninson, I.B. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum. Genet. 1987, 77, 142-144.
64. Chin, J.E.; Soffir, R.; Noonan, K.E.; Choi, K.; Roninson, I.B. Structure and expression of the human MDR1 (P-glycoprotein) gene family. Mol. Cell Biol. 1989, 9, 3808-3820.
65. 185 with an altered pattern of multidrug resistance. Biochem. Biophys. Res. Commun. 1989, 162, 224-231.
66. Stein, U.; Walther, W.; Wunderlich, V. Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. Eur. J. Cancer 1994, 30A, 1541-1545.
67. Mickley, L.A.; Lee, J.S.; Weng, Z.; Zhan, Z.; Alvarez, M.; Wilson, W.; Bates, S.E.; Fojo. T. Genetic polymorphism in MDR-1: A tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 1998, 91, 1749-1756.
68. Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold, H.P.; Brockmoller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichelbaum, M.; Brinkmann, U. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 2000, 97, 3473-3478.
69. Greiner, B.; Eichelbaum, M.; Fritz, P.; Kreichgauer, H.P.; von Richter, O.; Zundler, J.; Kroemer, H.K. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 1999, 104, 147-153.
70. Johne, A.; Brockmöller, J.; Bauer, S.; Maurer, A.; Langheinrich, M.; Roots, I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin. Pharmacol. Ther. 1999, 66, 338-345.
71. Ito, S.; Ieiri, I.; Tanabe, M.; Suzuki, A.; Higuchi, S.; Otsubo, K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001, 11, 175-184.
72. Cascorbi, I.; Gerloff, T.; Johne, A.; Meisel, C.; Hoffmeyer, S.; Schwab, M.; Schaeffeler, E.; Eichelbaum, M.; Brinkmann, U.; Roots, I. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 2001, 69, 169-174.
73. Tanabe, M.; Ieiri, I.; Nagata, N.; Inoue, K.; Ito, S.; Kanamori, Y.; Takahashi, M.; Kurata, Y.; Kigawa, J.; Higuchi, S.; Terakawa, N.; Otsubo, K. Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 2001, 297, 1137-1143.
74. Kim, R.B.; Leake, B.F.; Choo, E.F.; Dresser, G.K.; Kubba, S.V.; Schwarz, U.I.; Taylor, A.; Xie, H.G.; McKinsey, J.; Zhou, S.; Lan, L.B.; Schuetz, J.D.; Schuetz, E.G.; Wilkinson, G.R. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 2001, 70, 189-199.
75. Kroetz, D.L.; Pauli-Magnus, C.; Hodges, L.M.; Huang, C.C.; Kawamoto, M.; Johns, S.J.; Stryke, D.; Ferrin, T.E.; DeYoung, J.; Taylor, T.; Carlson, E.J.; Herskowitz, I.; Giacomini, K.M.; Clark, A.G. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003, 13, 481-494.
76. Ameyaw, M.M.; Regateiro, F.; Li, T.; Liu, X.; Tariq, M.; Mobarek, A.; Thornton, N.; Folayan, G.O.; Githang'a, J.; Indalo, A.; Ofori-Adjei, D.; Price-Evans, D.A.; McLeod, H.L. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001, 11, 217-221.
77. Schaeffeler, E.; Eichelbaum, M.; Brinkmann, U.; Penger, A.; Asante-Poku, S.; Zanger, U.M.; Schwab, M. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001, 358(9279), 383-384.
78. Sakaeda, T.; Nakamura, T.; Horinouchi, M.; Kakumoto, M.; Ohmoto, N.; Sakai, T.; Morita, Y.; Tamura, T.; Aoyama, N.; Hirai, M., Kasuga, M.; Okumura, K. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 2001, 18, 1400-1404.
79. Bernal, M.L.; Sinues, B.; Fanlo, A.; Mayayo, E. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther. Drug Monit. 2003, 25, 107-111.
80. Balram, C.; Sharma, A.; Sivathasan, C.; Lee, E.J. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br. J. Clin. Pharmacol. 2003, 56, 78-83.
81. Chelule, P.K.; Gordon, M.; Palanee, T.; Page, T.; Mosam, A.; Coovadia, H.M.; Cassol, S. MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa. Clin. Pharmacol. Ther. 2003, 74, 195-196.
82. Jamroziak, K.; Balcerczak, E.; Mlynarski, W.; Mirowski, M.; Robak, T. Distribution of allelic variants of functional C3435T polymorphisms of drug transporter MDR1 gene in a sample of polish population. Pol. J. Pharmacol. 2002, 54, 495-500.
83. Gaikovitch, E.A.; Cascorbi, I.; Mrozikiewicz, P.M.; Brockmoller, J.; Frotschl, R.; Kopke, K.; Gerloff, T.; Chernov, J.N.; Roots, I. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur. J. Clin. Pharmacol. 2003, 59, 303-312.
84. Horinouchi, M.; Sakaeda, T.; Nakamura, T.; Morita, Y.; Tamura, T.; Aoyama, N.; Kasuga, M.; Okumura, K. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: Functional relevance to pharmacokinetics of digoxin. Pharm. Res. 2002, 19, 1581-1585.
85. Furuno, T.; Landi, M.T.; Ceroni, M.; Caporaso, N.; Bernucci, I.; Nappi, G.; Martignoni, E.; Schaeffeler, E.; Eichelbaum, M.; Schwab, M.; Zanger, U.M. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2002, 12, 529-534.
86. Zheng, H.; Webber, S.; Zeevi, A.; Schuetz, E.; Zhang, J.; Lamba, J.; Bowman, P.; Burckart, G.J. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum. Immunol. 2002, 63, 765-770.
87. Chowbay, B.; Cumaraswamy, S.; Cheung, Y.B.; Zhou, Q.; Lee, E.J.D. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003, 13, 89-95.
88. Siddiqui, A.; Kerb, R.; Weale, M.E.; Brinkmann, U.; Smith, A.; Goldstein, D.B.; Wood, N.W.; Sisodiya, S.M. Assiciation of multidrug resistance in pilepsy with apolymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 2003, 348, 1442-1448.
89. + natural killer cells. Pharmacogenetics 2001, 11, 293-298.
90. Oselin, K.; Nowakowski-Gashaw, I.; Mrozikiewicz, P.M.; Wolbergs, D.; Pahkla, R.; Roots, I. Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene. Eur. J. Clin. Invest. 2003, 33, 261-267.
91. Oselin, K.; Gerloff, T.; Mrozikiewicz, P.M.; Pahkla, R.; Roots, I. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam. Clin. Pharmacol. 2003, 17, 463-469.
92. Nakamura, T.; Sakaeda, T.; Horinouchi, M.; Tamura, T.; Aoyama, N.; Shirakawa, T.; Matsuo, M.; Kasuga, M.; Okumura, K. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther. 2002, 71, 297-303.
93. Goto, M.; Masuda, S.; Saito, H.; Uemoto, S.; Kiuchi, T.; Tanaka, K.; Inui, K. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002, 12, 451-457.
94. Siegmund, W.; Ludwig, K.; Giessmann, T.; Dazert, P., Schroeder, E.; Sperker, B.; Warzok, R.; Kroemer, H.K.; Cascorbi, I. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther. 2002, 72, 572-583.
95. C3435T polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol. 2002, 13, 1847-1854.
96. Illmer, T.; Schuler, U.S.; Thiede, C.; Schwarz, U.I.; Kim, R.B.; Gotthard, S.; Freund, D.; Schakel, U.; Ehninger, G.; Schaich, M. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002, 62, 4955-4962.
97. Efferth, T.; Sauerbrey, A.; Steinbach, D.; Gebhart, E.; Drexler, H.G.; Miyachi, H.; Chitambar, C.R.; Becker, C.M.; Zintl, F.; Humeny, A. Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int. J. Oncol. 2003, 23, 509-517.
98. Moriya, Y.; Nakamura, T.; Horinouchi, M,; Sakaeda, T.; Tamura, T.; Aoyama, N.; Shirakawa, T.; Gotoh, A.; Fujimoto, S.; Matsuo, M.; Kasuga, M.; Okumura K. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull. 2002, 25, 1356-1359.
99. Kimchi-Sarfaty, C.; Gribar, J.J.; Gottesmann, M.M. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 2002, 62, 1-6.
100. Morita, N.; Yasumori, T.; Nakayama, K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem. Pharmacol. 2003, 65, 1843-1852.
101. Synold, T.W.; Dussault, I.; Forman, B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Med. 2001, 7, 584-590.
102. Becquemont, L.; Verstuyft, C.; Kerb, R.; Brinkmann, U.; Lebot, M.; Jaillon, P.; Funck-Brentano, C. Effect of grapefruit juice oil digoxin pharmacokinetics in humans. Clin. Pharmacol. Ther. 2001, 70, 311-316.
103. Verstuyft, C.; Strabach, S.; El-Morabet, H.: Kerb, R.; Brinkmann, U.; Dubert, L.; Jaillon, P.; Funck-Brentano, C.; Trugnan, G.; Becquemont, L. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin. Pharmacol. Ther. 2003, 73, 51-60.
104. Verstuyft, C.; Schwab, M.; Schaeffeler, E.; Kerb, R.; Brinkmann, U.; Jaillon, P.; Funck-Brentano, C.; Becquemont, L. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur. J. Clin. Pharmacol. 2003, 58, 809- 812.
105. Drescher, S.; Schaeffeler, E.; Hitzl, M.; Hofmann, U.; Schwab, M.; Brinkmann, U.; Eichelbaum, M.; Fromm, M.F. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. 2002, 53, 526-534.
106. Gerloff, T.; Schaefer, M.; Johne, A.; Oselin, K.; Meisel, C.; Cascorbi, I.; Roots, I. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br. J. Clin. Pharmacol. 2002, 54, 610-616.
107. Min, D.I.; Ellingrod, V.L. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit. 2002, 24, 400-404.
108. Kurata, Y.; Ieiri, I.; Kimura, M.; Morita, T.; Irie, S.; Urae, A.; Ohdo, S.; Ohtani, H.; Sawada, Y.; Higuchi, S.; Otsubo, K. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharmacol. Ther. 2002, 72, 209-219.
109. Fellay, J.; Marzolini, C.; Meaden, E.R.; Back, D.J.; Buclin, T.; Chave, J.P.; Decosterd, L.A.; Furrer, H.; Opravil, M.; Pantaleo, G.; Retelska, D.; Ruiz, L.; Schinkel, A.H.; Vernazza, P.; Eap, C.B.; Telenti, A. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002, 359(9300), 30-36.
110. Johne, A.; Kopke, K.; Gerloff, T.; Mai, I.; Rietbrock, S.; Meisel, C.; Hoffmeyer, S.; Kerb, R.; Fromm, M.F.; Brinkmann, U.; Eichelbaum, M.; Brockmoller, J; Cascorbi, I.; Roots, I. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 2002, 72, 584-594.
111. von Ahsen, N.; Richter, M.; Grupp, C.; Ringe, B.; Oellerich, M., Armstrong, V.W. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. 2001, 47, 1048-1052.
112. Yates, C.R.; Zhang, W.; Song, P.; Li, S.; Gaber, A.O.; Kotb, M.; Honaker, M.R.; Alloway, R.R.; Meibohm, B. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J. Clin. Pharmacol. 2003, 43, 555-564.
113. Zheng, H.; Webber, S.; Zeevi, A.; Schuetz, E.; Zhang, J.; Bowman, P.; Boyle, G.; Law, Y.; Miller, S.; Lamba, J.; Burckart, G.J. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polyrnorphisms. Am. J. Transplant. 2003, 3, 477-483
114. Anglicheau, D.; Verstuyft, C.; Laurent-Puig, P.; Becquemont, L.; Schlageter, M.H.; Cassinat, B.; Beaune, P.; Legendre, C.; Thervet, E. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. 2003, 14, 1889-1896.
115. Goh, B.C.; Lee, S.C.; Wang, L.Z.; Fan, L.; Guo, J.Y.; Lamba, J.; Schuetz, E.; Lim, R.; Lim, H.L.; Ong, A.B.; Lee, H.S. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J. Clin. Oncol. 2002, 20, 3683-3690.
116. Morita, Y.; Sakaeda, T.; Horinouchi, M.; Nakamura, T.; Kuroda, K.; Miki, I.; Yoshimura, K.; Sakai, T.; Shirasaka, D.; Tamura, T.; Aoyama, N.; Kasuga, M.; Okumura, K. MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm. Res. 2003, 20, 552-556.
117. Yamauchi, A.; Ieiri, I.; Kataoka, Y.; Tanabe, M.; Nishizaki, T.; Oishi, R.; Higuchi, S.; Otsubo, K.; Sugimachi, K. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 2002, 74, 571-578.
118. Nasi, M.; Borghi, V.; Pinti, M.; Bellodi, C.; Lugli, E.; Maffei, S.; Troiano, L.; Richeldi, L.; Mussini, C.; Esposito, R.; Cossarizza, A. MDR1 C3435T genetic polymorphism dose not influence the response to antiretroviral therapy in drug-naïve HIV-positive patients. AIDS 2003, 17, 1696-1698.
119. Persidis, A. Cancer multidrug resistance. Nature Biotechnol. 1999, 17, 94-95.
120. Szabo, D.; Keyzer, H.; Kaiser, H.E.; Molnar, J. Reversal of multidrug resistance of tumor cells. Anticancer Res. 2000, 20, 4261-4274.
121. Bradshaw, D.M.; Arceci, R.J. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J. Clin. Oncol. 1998, 16, 3674-3690.
122. Garraway, L.A.; Chabner, B. MDR1 inhibition: less resistance or less relevance? Eur. J. Cancer 2002, 38, 2337-2340.
123. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
124. Mattern, J. Drug resistance in cancer: a multifactorial problem. Anticancer Res. 2003, 23, 1769-1772.
125. Stein, W.D. Reversers of the multidrug resistance transporter P-glycoprotein. Curr. Opin. Investig. Drugs 2002, 3, 812-817.
126. Nakahara, T.; Sakaeda, T.; Nakamura, T.; Tamura, T.; Nishioka, C.; Aoyama, N.; Okamura, N.; Shirakawa, T.; Gotoh, A.; Kamigaki, T.; Ohno, M.; Kuroda, Y.; Matsuo, M.; Kasuga, M.; Okumura, K. Chemosensitivity assessed by collagen gel droplet embedded culture drug sensitivity test, and MDR1, MRP1, and MRP2 mRNA expression in human colorectal adenocarcinoma. Pharm. Res. 2003, 21, 406-412.
127. Nishioka, C.; Sakaeda, T.; Nakamura, T.; Moriya, Y.; Tamura, T.; Nakahara, T.; Aoyama, N.; Kamigaki, T.; Ohno, M.; Kuroda, Y.; Kasuga, M.; Okumura, K. Chemosensitivity assessed by collagen gel droplet embedded culture drug sensitivity test (CD-DST), and MDR1, MRP1, MRP2 genotypes in human colorectal adenocarcinoma. Biol. Pharm. Bull. 2003, unpublished results.
128. Toffoli, G.; Cecchin, E.; Corona, G.; Boiocchi, M. Pharmacogenetics of irinotecan. Curr. Med. Chem. Anti-Cancer Agents 2003, 3, 225-237.
129. Schwab, M.; Schaeffeler, E.; Marx, C.; Fromm, M.F.; Kaskas, B.; Metzler, J.; Stange, E.; Herfarth, H.; Schoelmerich, J.; Gregor, M.; Walker, S.; Cascorbi, I.; Roots, I.; Brinkmann, U.; Zanger, U.M.; Eichelbaum, M. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003, 124, 26-33.
130. Panwala, C.M.; Jones, J.C.; Viney, J.L. A novel model of inflammatory bowel disease: Mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J. Immunol. 1998, 161, 5733-5744.
131. Maggio-Price, L.; Shows, D.; Waggie, K.; Burich, A.; Zeng, W.; Escobar, S.; Morrissey, P.; Viney, J.L. Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1 a-1-) mice. Am. J. Pathol. 2002, 160, 739-751.
132. Ho, G.T.; Moodie, F.M.; Satsangi, J. Multidrug resistance 1 gene (P-glycoprotein 170): An important determinant in gastrointestinal diseases? Gut 2003, 52, 759-766.
133. Humeny, A.; Rodel, F.; Rodel, C.; Sauer, R.; Fuzesi, L.; Becker, C.; Efferth, T. MDR1 single nucleotide polymorphism C3435T in normal colorectal tissue and colorectal carcinoma detected by MALDI-TOF mass spectrometry. Anticancer Res. 2003, 23, 2735-2740.
134. Drozdzik, M.; Bialecka, M.; Mysliwiec, K.; Honczarenko, K.; Stankiewicz, J.; Sych, Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003, 13, 259-263.
135. Fromm, M.F. Genetically determined differences in P-glycoprotein function: Implications for disease risk. Toxicology 2002, 181/182, 299-303.
136. Johnstone, R.W.; Ruefli, A.A.; Smyth, M.J. Multiple physiological functions for multidrug trnsporter P-glycoprotein? Trends Biochem. Sci. 2000, 25, 1-6.
137. Johnstone, R.W.; Ruefli, A.A.; Tainton, K.M.; Smyth, M.J. A role for P-glycoprotein in regulating cell death. Leukemia Lymphoma 2000, 38, 1-11.
138. Smyth, M.J.; Krasovskis, E.; Sutton, V.R.; Johnstone, R.W. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc. Natl. Acad. Sci. USA 1998, 95, 7024-7029.
139. Johnstone, R.W.; Cretney, E.; Smyth, M.J. P-Glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999, 93, 1075-1085.
140. Sakaeda, T.; Nakamura, T.; Hirai, M.; Kimura, T.; Wada, A.; Yagami, T.; Kobayashi, H.; Nagata, S.; Okamura, N.; Yoshikawa, T.; Shirakawa, T.; Gotoh, A.; Matsuo, M.; Okumura, K. MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling. Pharm. Res. 2002, 19, 1323-1329.
141. Lee, C.G.L.; Ramachandra, M.; Jeang, K.T.; Martin, M.A.; Pastan, I.; Gottesman, M.M. Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J. 2000, 14, 516-522.
142. Sundseth, R.; MacDonald, G.; Ting, J.; King, A.C. DNA elements recognizing NF-Y and Sp1 regulate the human multidrug-resistance gene promoter. Mol. Pharmacol. 1997, 51, 963-971.
143. Cornwell, M.M.; Smith, D.E. SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J. Biol. Chem. 1993, 268, 19505-19511.
144. Ohga, T.; Uchiumi, T.; Makino, Y.; Koike, K.; Wada, M.; Kuwano, M.; Kohno, K. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J. Biol. Chem. 1998, 273, 5997-6000.
145. Koike, K.; Uchiumi, T.; Ohga, T.; Toh, S.; Wada, M.; Kohno, K.; Kuwano, M. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett. 1997, 417, 390-394.
146. Jin, S.; Scotto, K.W. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol. Cell Biol. 1998, 18, 4377-4384.
147. Labialle, S.; Gayet, L.; Marthinet, E.; Rigal, D.; Baggetto, L.G. Transcriptional regulation of the human MDR1 gene at the level of the inverted MED-1 promoter region. Ann. N. Y. Acad. Sci. 2002, 973, 468-471.
148. Takara, K.; Takagi, K.; Tsujimoto, M.; Ohnishi, N.; Yokoyama, T. Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor (SXR) mRNA. Biochem. Biophys. Res. Commun. 2003, 306, 116-120.
149. Yagüe, E.; Armesilla, A.L.; Harrison, G.; Elliott, J.; Sardini, A.; Higgins, C.F.; Raguz, S. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J. Biol. Chem. 2003, 278, 10344-10352.
150. Zhang, J.; Kuehl, P.; Green, E.D.; Touchman, J.W.; Watkins, P.B.; Daly, A.; Hall, S.D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Wrighton, S.A.; Hancock, M., Kim, R.B.; Strom, S.; Thummel, K.; Russell, C.G.; Hudson, J.R.Jr.; Schuetz, E.G.; Boguski M.S. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001, 11, 555-572.
151. Hustert, E.; Zibat, A.; Presecan-Siedel, E.; Eiselt, R.; Mueller, R.; Fuss, C.; Brehm, I.; Brinkmann, U.; Eichelbaum, M.; Wojnowski, L.; Burk, O. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos. 2001, 29, 1454-1459.
152. Sakaeda, T.; Okamura, N.; Nagata, S.; Yagami, T.; Horinouchi, M.; Okumura, K.; Yamashita, F.; Hashida, M. Molecular and pharmacokinetic properties of 222 commercially available oral drugs in human. Biol. Pharm. Bull. 2001, 24, 935-940.
153. Takara, K.; Tsujimoto, M.; Ohnishi, N.; Yokoyama. T. Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells. Biochem. Biophys. Res. Commun. 2002, 292, 190-194.
154. Takara, K.; Tsujimoto, M.; Ohnishi, N.; Yokoyama, N. Effects of continuous exposure to digoxin on MDR1 function and expression in Caco-2 cells. J. Pharm. Pharmacol. 2003, 55, 675-681.
155. Schuetz, E.G.; Schinkel, A.H.; Relling, M.V.; Schuetz, J.D. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. USA 1996, 93, 4001-4005.
156. Asghar, A.; Gorski, J.C.; Haehner-Naniels, B.; Hall, S.D. Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metabol. Dispos. 2002, 30, 20-26.
157. Geick, A.; Eichelbaum, M.; Burk, O. Nuclear receptor response elements mediate induction of intestinal MDR by rifampin. J. Biol. Chem. 2001, 276, 14581-14587.
158. Muller, C.; Bailly, J.D.; Goubin, F.; Laredo, J.; Jaffrézou, J.P.; Bordier, C.; Laurent, G. Verapamil decreases P-glycoprotein expression in multidrug-resistant human leukemic cell lines. Int. J. Cancer 1994, 56, 749-754.
159. Muller, C.; Goubin, F.; Ferrandis, E.; Cornil-Scharwtz, I.; Bailly, J.D.; Bordier, C.; Benard, J.; Sikic, B.I.; Laurent, G. Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells. J. Pharmacol. Exp. Ther. 1995, 47, 51-56.
160. 2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur. J. Pharm. Sci. 2002, 16, 159-165.
161. Sukhal, M.; Piquette-Miller, M. Regulation of the multidrug resistance genes by stress signals. J. Pharm. Pharmacuet. Sci. 2000, 3, 268-280.
162. Cardon, L.R.; Palmer, L.J. Population stratification and squrious allelic association. Lancet 2003, 361, 598-604.
163. Nishizato, Y.; Ieiri, I.; Suzuki, H.; Kimura, M.; Kawabata, K.; Hirota, T.; Takene, H.; Irie, S.; Kusuhara, K.; Urasaki, Y.; Urae, A.; Higuchi, S.; Otsubo, K.; Sugiyama, Y. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 2003, 73, 554-565.
164. Innocenti, F.; Iyer, L.; Ratain, M.J. Pharmacogenetics - A tool for individualizing antineoplastic therapy. Clin. Pharmacokinet. 2000, 39, 315-325.
165. Innocenti, F.; Ratain, M.J. Update on pharmacogenetics in cancer chemotherapy. Eur. J. Cancer 2002, 38, 639-644.
166. Sekine, I.; Saijo, N. Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents, Ann. Oncol. 2001, 12, 1515-1525.
167. Sachidanandam, R.; Weissman, D.; Schmidt, S.C.; Kakol, J.M,; Stein, L.D.; Marth, G.; Sherry, S.; Mullikin, J.C.; Mortimore, B.J.; Willey, D.L,; Hunt, S.E.; Cole, C.G.; Coggill, P.C.; Rice, C.M.; Ning, Z.; Rogers, J.; Bentley, D.R.; Kwok, P.Y.; Mardis, E.R.; Yeh, R.T.; Schultz, B.; Cook, L.; Davenport, R.; Dante, M.; Fulton, L.; Hillier, L.; Waterston, R.H.; McPherson, J.D.; Gilman, B.; Schaffner, S.; van Etten, W.J.; Reich, D.; Higgins, J.; Daly, M.J.; Blumenstiel, B.; Baldwin, J.; Stange-Thomann, N.; Zody, M.C.; Linton, L.; Lander, E.S.; Altshuler, D (International SNP Map Working Group). A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001, 409(6822), 928-933.
168. Stephens, J.C.; Schneider, J.A.; Tanguay, D.A.; Choi, J.; Acharya, T.; Stanley, S.E.; Jiang, R.; Messer, C.J.; Chew, A.; Han, J.H., Duan, J.; Carr, J.L.; Lee, M.S.; Koshy, B.; Kumar, A.M.; Zhang, G.; Newell, W.R.; Windemuth, A.; Xu, C.; Kalbfleisch, T.S.; Shaner, S.L.; Arnold, K.; Schulz, V.; Drysdale, C.M.; Nandabalan, K.; Judson, R.S.; Ruano, G.; Vovis, G.F. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001, 293, 489-493.
169. Gwee, P.C.; Tang, K.; Chua, J.M.Z.; Lee, E.J.D., Chong, S.S. Lee, C.G.L. Simulatneous genotyping of seven single-nucleotide polymorphisms in the MDR1 gene by single-tube multiplex minisequencing. Clin. Chem. 2003, 49, 672-676.
170. Song, P.; Li, S.; Meibohm, B.; Gaber, A.O.; Honaker, M.R.; Kotb, M.; Yates, C.R. Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. AAPS. Pharm. Sci. 2002, 4, A29.
171. Marques, L.P.J.; Cavaco, I.; Pinheiro, J.P.; Ribeiro, V.; Ferreira, G.N. Electrochemical DNA sensor for detection of single nucleotide polymorphisms. Clin. Chem. Lab. Med. 2003, 41, 475-481.
172. Schaeffeler, E.; Lang, T.; Zanger, U.M.; Eichelbaum, M.; Schwab, M. High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC. Clin. Chem. 2001, 47, 548-555.